Latest News

Opinion: The U.S. shouldn’t use the ‘QALY’ in drug cost-effectiveness reviews

What’s a year of life worth?

That question is at the heart of a metric called the quality-adjusted life year that is increasingly being used to make decisions about paying for new drugs.

Read the rest…

Source link

Related posts

Variantyx Launches Its Whole Genome Sequencing (WGS)-Based In-Silico Panel Program at National Society of Genetic Counselors Annual Conference


Genetics determine whether you are an early riser or a night owl


BioAxone BioSciences Awarded Fast-Track SBIR Grant for Continued Development of Rho Kinase 2 Inhibitor


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy